domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -71,6 +71,12 @@ The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE hea
 
 WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16*
+
+Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -59,6 +59,12 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2
 
 The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16*
+
+Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.json

@@ -0,0 +1,26 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 3,
+    "rejected": 1,
+    "fixes_applied": [
+      "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:set_created:2026-03-16",
+      "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d",
+      "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category"
+    ],
+    "rejections": [
+      "digital-behavioral-support-combined-with-glp1-achieves-44-percent-greater-weight-loss-than-medication-alone-while-halving-drug-requirements.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes.md

@@ -7,9 +7,13 @@ date: 2025-01-01
 domain: health
 secondary_domains: []
 format: study
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, adherence, digital-health, weight-loss, tirzepatide, behavioral-support, obesity]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -60,3 +64,12 @@ A retrospective cohort service evaluation study published in the Journal of Medi
 PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate)
 WHY ARCHIVED: Convergent evidence that digital behavioral support partially solves the GLP-1 adherence problem — changes the economic model under capitation if sustained
 EXTRACTION HINT: Focus on the half-dose finding (cost efficiency) and the convergence with WHO guidelines (behavioral combination is now international standard). Scope carefully — observational, not RCT.
+
+
+## Key Facts
+- Voy platform components include live group video coaching, text-based support, educational content, weight monitoring, and adherence tracking
+- UK Voy study showed high withdrawal rate in non-engaged group limiting generalizability
+- Tirzepatide users outperformed semaglutide users: 13.9% vs 9.5% at 5 months in Voy cohort
+- WHO December 2025 guidelines recommend combining GLP-1 with intensive behavioral therapy
+- Danish study was 64 weeks duration, UK Voy study was 5 months
+- All three studies (UK, Danish, Wiley) were retrospective/observational, not RCTs